**Scope Guidelines**

**Data Descriptors** submitted to *Scientific Data* should provide detailed descriptions of valuable research datasets, including the methods used to collect the data and technical analyses supporting the quality of the measurements. Data Descriptors focus on helping others reuse data, rather than testing hypotheses, or presenting new interpretations, methods or in-depth analyses. Relevant datasets must be deposited in an appropriate public repository prior to Data Descriptor submission, and their completeness will be considered during editorial evaluation and peer review. The data must be made publicly available without restriction in the event that the Data Descriptor is accepted for publication (excepting reasonable controls related to human privacy issues or public safety).

### Title

Mass spectrometry peptidomics data from infected and uninfected porcine wounds

### Authors

Fredrik Forsberg1, Sven Kjellström2, Jitka Petrlova1, Manoj Puthia1, Artur Schmidtchen1, Johan Malmström3, Erik Hartman3

**Affiliations**

1. Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, Lund, Sweden

2. Division of Mass Spectrometry, Department of Clinical Sciences, Lund University, Lund, Sweden

3. Division of Infection Medicine, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden

corresponding author: Fredrik Forsberg (fredrik.forsberg@med.lu.se)

### Abstract

Recently, mass spectrometry based peptidomics studies have proven useful in the identification of biomarkers and bioactive peptide-based therapeutics. Here, we present a dataset consistent of temporal wound fluid peptidomics data from highly defined porcine models. Wound fluids from porcine wounds infected with *Staphylococcus aureus* and *Pseudomonas aeruginosa*, and uninfected controls, were sampled at different timepoints of the infection. Peptides were extracted from the samples, followed by liquid chromatography tandem mass spectrometry analysis in data dependent acquisition mode. The resulting spectra are deposited to an online repository, allowing for database searching and subsequent peptidomic analysis of the infected and uninfected normal wound fluid peptidome.

### Background & Summary

Peptides are short sequences of amino acids which are naturally produced in organisms, both through the translation of mRNA but importantly also through the degradation of proteins. These peptides play important roles in different biological systems, such as being messengers in signalling pathways1 and by providing antimicrobial properties during infection2,3,4. Peptidomics is the study of large sets of peptides from biological samples and has proven to be pivotal in the characterization of peptides and protein degradation under different physiological conditions as well as in the search for therapeutic peptides. Identification and quantification of peptides is necessary to conduct peptidomic analyses. Commonly, liquid chromatographic (LC) separation followed by mass spectrometry (MS) analysis is used for this purpose5.

During a wound infection, a combination of host and pathogen derived proteases create an environment with increased proteolytic activity. The host uses proteases to remodel tissue and fight the invasion of bacteria, whereas bacterial proteases may promote colonization6,7,8,9. By investigating the resulting peptidome during different wound infection conditions, further understanding of this environment and mechanism could be gained.

Chronic wounds pose a large economic burden on society and life quality burden for patients. The prevalence of these wounds is likely to increase with an aging population and more life-style related diseases10. Further, pathogens such as *Staphylococcus aureus* and *Pseudomonas aeruginosa* are two of the most prevalent bacteria in infected wounds11. They are considered of high and critical priority respectively by the World Health Organization due to their developed resistance against current antibiotics12. Therefore, identifying novel means of diagnosing and treating such wounds is of extreme importance.

A study was carried out to identify differences in the peptidomic landscape of wound fluids depending on the presence and type of pathogen, while also employing a newly developed analysis algorithm with the potential to remove large amounts of redundancy in peptidomic datasets13. This was achieved by generating LC-MS/MS data from wound fluids derived from highly defined infected porcine wounds (Fig. 1). Here, we present descriptions and access to the datasets. We believe that the vastness of the peptidomic data yields many opportunities to analyze it using different methods to gain novel insights about the mechanisms underlying protein degradation in infected wounds.

### Methods

**Study design**

The data presented here was utilized to analyze the peptidomic landscape of infected wounds in Hartman et al. (2024). Briefly, wounds were generated on Göttingen minipigs, whereafter they were infected with either *S. aureus* or *P. aeruginosa*, both, or not infected and used as control. The wounds were covered with wound dressings, which absorbed the wound fluid generated in the wound healing process (Fig. 1a). The dressings were collected every 24 hours for 2-3 days depending on the sample type. Four of the wounds infected by *S. aureus* on day 1 were infected with *P. aeruginosa* on day 2, creating a double infection. Additionally, some of the wounds infected by *S. aureus* were contaminated by *P. aeruginosa* on the infection day, creating a set of samples which undergo an accidental double infection (Fig. 1b).

The proteomic content of the samples was discarded by filtration (Fig. 1c), and the subsequent peptidomic sample was analyzed with liquid chromatography tandem mass spectrometry (LC-MS/MS) in data dependent acquisition mode on an Evosep One LC (Evosep, Denmark) coupled to a timsTOF Pro MS (Bruker, USA). The data was searched with PEAKS X and deposited to ProteomeXchange (Fig. 1d). This was performed in a non-blinded manner. A stratified blinded random subset of samples from day 1, containing 4 samples from each single infection and control condition, were re-analyzed. The re-analysis was conducted 8 months after the original samples using the same conditions except for that the MS had been changed to a timsTOF HT (Bruker, USA) (Fig 1b).

**Pig acute wound fluid collection**

Partial thickness wounds were induced to Göttingen minipigs, which were then either infected with *S. aureus* or *P.aeruginosa*, both, or kept uninfected as control samples. Polyurethane dressings were used to dress the wounds and were changed after 24 and 48 hours. The old dressings were soaked in 10 mM Tris, and the fluids were extracted using a syringe. A subset of the *S. aureus* infected wounds was accidentally cross contaminated with *P. aeruginosa*. Another set of the *S. aureus* infected wounds were infected with *P. aeruginosa* after 24 hours, and these dressings were also collected and extracted 72 hours after the initial *S. aureus* infection. Extracted fluids were then supplemented with Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific, USA) and kept at -80°C until further use.

**Wound fluid peptide extraction**

500 μg of protein (determined with Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, USA) as per provided instructions) was diluted to 100 μl with 10 mM Tris at pH 7.4. 300 μl of 8 M urea diluted in 10 mM Tris at pH 7.4, supplemented with 0.067% RapiGest SF (Waters, USA) was then added followed by an incubation at room temperature for 30 minutes. 100 μl 6 M urea in 10 mM Tris at pH 7.a was added to Microcon - 30 centrifugal filter units and centrifuged at 10000 RCF for 15 minutes at room temperature (RT). After this the wound fluid samples were added to the centrifugal filters, and centrifuged at 10000 RCF for 30 minutes at RT. Finally, another 100 μl of 6 M urea in 10 mM Tris at pH 7.4 was centrifuged through the filter units at 10000 RCF for 5 minutes at RT and the filtrate was stored at -20°C.

**Acidification and solid phase extraction**

1 μl 100% formic acid (FA) was added to 60 μl of each extracted peptide sample. 100 μl 100% acetonitrile (ACN) + 0.1% FA was added to UltraMicro Spin Columns (The Nest Group, USA) which were centrifuged at 800 RCF for 1 minute at room temperature. All further centrifugation steps in this section were performed this way. 100 μl 2% ACN + 0.1% trifluoroacetic acid (TFA) was centrifuged through the columns, twice, before adding the samples and performing an additional centrifugal step. Lastly, 100 μl 70% ACN + 0.1% TFA was centrifuged through the columns to elute the sample which was then dried in an Eppendorf Concentrator plus (Eppendorf, Germany).

**LC-MS/MS**

The dried peptide samples were then dissolved in 30 μl 2% ACN + 0.1% FA, before being loaded onto Evotip Pure columns (Evosep, Denmark) according to the provided instructions, apart from that the samples were not dissolved in 20 µl 0.1% FA before loading. The samples were analyzed by LC/MS-MS on an Evosep One LC (Evosep, Denmark) coupled with a timsTOF Pro mass spectrometer (Bruker, USA). The LC used a EV1137 Performance Column - 15 cm x 150 µm, with 1.5 µm ReproSil-Pur C18 beads (Evosep, Denmark). The accompanying 30 samples per day program was used for separation. The MS used the DDA PASEF mode, with 10 PASEF scans every acquisition cycle. Accumulation and ramp times were set to 100 ms, precursors with a +1 charge were ignored, and target intensity was set to 20000, with dynamic exclusion active, at 0.4 min. Isolation width was set to 2 at 700 Th and 3 at 800 Th.

**Database search**

The data from the LC-MS/MS runs were searched with PEAKS X. UniProtKB reviewed (Swiss-Prot) protein list of pig (organism\_id:9823) proteins was used as a database, but with fibrinogen alpha chain (FIBA\_PIG) and fibrinogen beta chain (FIBB\_PIG) being changed to the UniProt KB unreviewed (TrEMBL) versions F1RX36\_PIG and F1RX37\_PIG. The list was downloaded May 11th, 2023. Data refinement was set to merge scans and correct precursor based on mass and charge states with charges between 1 and 4. It was also set to associate features between 2 and 8. Precursor tolerance was set to 20.0 ppm using monoisotopic mass and fragment tolerance was set to 0.03 Da. 1 modification per peptide was allowed with oxidation (M, +15.99) being the only possible modification. Results were filtered at 1% FDR with ≥1 unique peptide for each protein. FDR was set to be estimated with decoy-function.

### Data Records

Both the raw mass spectrometry data (.d folders generated by Bruker Compass) as well as the database search of the data (.mgf and .mzid.gz generated by PEAKS X) have been uploaded to ProteomeXchange as a part of the public dataset PXD048892 along with a design file for sample identification (.csv) (<https://dx.doi.org/10.6019/PXD048892>). Additionally, similar files from the blinded re-run of samples have been uploaded to ProteomeXchange under the identifier PXD055074 (<https://dx.doi.org/10.6019/PXD055074>).

### Technical Validation

To characterize the dataset, general characteristics of the different groups were summarized (Fig. 2). Unique peptide overlap was summarized, with more unique peptides appearing in the *S. aureus* (2705)and *P. aeruginosa* (5005) groups compared to the control group (410), while the number of peptides shared by all samples was 2128 (Fig 2a). The number of identified peptides decreases over time (Fig 2b). The mean length distribution weighted by the log2 intensities were similar for all sample types (Fig 2c). The log2 intensities were scaled to a mean of 0 and a unit variance. Thereafter, the dimensionality of the data was reduced using Uniform Manifold Approximation Projection (UMAP). Default settings were used as per the umap-learn python package (Fig 2d). The data cluster based on infection type and sampling day.

To validate that our peptide extraction and mass spectrometry methods are reproducible, 4 wound fluid samples from day 1 and each of the groups *S. aureus*, *P. aeruginosa*, and control were randomly selected, and the peptides were extracted as per the protocol described previously (Fig. 1c). The samples were blinded for the entire remaining sample preparation and analysis workflows. The peptides were analyzed by LC-MS/MS as previously, but using a timsTOF HT (Bruker, USA). The unique peptides identified in each sample group corresponded well with the samples analyzed previously (Fig 3a, b, c, d). Peptide length distributions are similar for the blinded re-analyzed samples compared to the original (Fig 3e). Lastly, the samples cluster together with the other samples from the same group and day when reducing dimensionality using UMAP (Fig 3f), showing that the method is robust and replicable.

### Usage Notes

The data deposited online was supplied as both raw output files and result files searched with PEAKS X. The raw files can be used for searching the data with different softwares or parameters than the one presented in this study. There are many ways to analyze the data in the resulting output files. MS intensities follow a lognormal distribution, so for comparative analyses the log of the intensities is computed prior to assuming normal distributions. The data contains missing values, and one can deal with these in different ways, e.g. through imputation. Further, to remove technical bias effects, normalization of the peptide intensities is commonly applied.

### Code Availability

No custom code was used to generate the data.

### Acknowledgements

We thank the Swedish National Infrastructure for Biological Mass Spectrometry (BioMS) for performing the LC-MS/MS analysis. We acknowledge support by grants from the Swedish Research Council (projects 2017-02341, 2018-05916 and 2020-02016 (A.S.), and 2023-02107 (J.M.)), Edvard Welanders Stiftelse and Finsenstiftelsen (Hudfonden) (A.S.), the Österlund Foundation (A.S.), and the Swedish Government Funds for Clinical Research (ALF) (A.S.).

### Author contributions

F.F. and E.H. wrote the manuscript. F.F., S.K. and J.P. performed the sample preparation. F.F. and S.K. performed the mass spectrometry analysis. M.P. and A.S. provided the porcine samples. A.S. and J.M. supervised the project.

### Competing interests

### The authors declare no competing interests.

### References

1. Wetzler, M. & Hamilton, P. Peptides as therapeutics. *Peptide Applications In Biomedicine, Biotechnology And Bioengineering*. 215-230 (Woodhead Publishing, 2018).
2. Saravanan, R. et al. Structural basis for endotoxin neutralisation and anti-inflammatory activity of thrombin-derived C-terminal peptides. *Nat. Commun*. **9**, 2762 (2018).
3. Huan, Y., Kong, Q., Mou, H. & Yi, H. Antimicrobial Peptides: Classification, design, application and research progress in multiple fields. *Front. Microbiol.* **11** (2020).
4. Mookherjee, N., Anderson, M. A., Haagsman, H. P. & Davidson, D. J. Antimicrobial host defence peptides: functions and clinical potential. *Nat. Rev. Drug Discov*. **19**, 311-332 (2020).
5. Schrader, M. Origins, technological advancement, and applications of peptidomics. *Peptidomics*. 3-47 (Humana, 2024).
6. Yager, D. R. & Nwomeh, B. C. The proteolytic environment of chronic wounds. *Wound Repair and Regeneration*. **7**, 433-441 (1999).
7. Serena, T. E., Bayliff, S. W. & Brosnan, P. J. Bacterial protease activity: a prognostic biomarker of early wound infection. *Journal of Wound Care*. **31**, 352-355 (2022).
8. Marshall, N. C., Finlay, B. B. & Overall, C. M. Sharpening host defenses during infection: proteases cut to the chase. *Mol. Cell. Proteom*. **16**, S161-S171 (2017).
9. Lindsay, S., Oates, A. & Bourdillon, K. The detrimental impact of extracellular bacterial proteases on wound healing. *Int. Wound J.* **14**, 1237-1247 (2017).
10. Olsson, M. et al. The humanistic and economic burden of chronic wounds: A systematic review. *Wound Rep. Reg*. **27**, 114-125 (2019).
11. Puca, V. et al. Microbial species isolated from infected wounds and antimicrobial resistance analysis: Data emerging from a three-years retrospective study. *Antibiotics*. **10**, 1162 (2021).
12. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. World Health Organization (WHO); 2017. Available from: <https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12>.
13. Hartman, E. et al. Peptide clustering enhances large-scale analyses and reveals proteolytic signatures in mass spectrometry data. *Nat Commun* **15**, 7128 (2024).

### Figures

### Figure Legends

Figure 1. Illustration of the sample generation, preparation and analysis protocol. **a** Wounds were generated onto pigs and overlaid with polyurethane dressings. The dressings absorb fluids from the wound. **b** Dressings were collected at every 24 hours for a 2–3-day period. The wound fluids were extracted from the dressings and protease inhibitor was added. **c** Wound fluids were filtered to separate the peptides from the proteins and other larger molecules found in the samples. **d** Filtered peptides were purified using solid phase extraction, before being analyzed by liquid chromatography-mass spectrometry in DDA mode. The results were then searched with PEAKS X and both the searched and raw files were uploaded to ProteomeXchange.

Figure 2. Characteristics of samples. S.a – *Staphylococcus aureus*, P.a – *Pseudomonas aeruginosa*, Ctrl – Uninfected control. **a** Venn diagram showing the distribution of unique peptides between the three sample groups S.a, P.a and Ctrl. **b** The number of unique peptides observed in each sample. **c** Kernel density estimates of peptide length weighted by the log2 peptide intensity. Separated on sample type and timepoint. **d** Uniform Manifold Approximation and Projection (UMAP) dimensionality reduction based on the log2-transformed intensities of all peptides in each sample.

Figure 3. Characterization and comparison with blinded replicates. S.a – *Staphylococcus aureus*, P.a – *Pseudomonas aeruginosa*, Ctrl – Uninfected control. **a**, **b**, **c** Venn diagram showing unique peptides observed in sample groups **a** Ctrl, **b** S.a and **c** P.a, compared to the same groups during the blinded rerun. **d** Venn diagram comparing the number of unique peptides in the blinded samples from the groups Ctrl, S.a and P.a. **e** Kernel density estimates of peptide length weighted by the log2 peptide intensity. Only including the blinded samples and their counterparts in the original dataset. **f** Uniform Manifold Approximation and Projection (UMAP) dimensionality reduction based on the log2-transformed intensities of all peptides in each sample with blinded rerun samples added.

### Tables

### Additional Formatting Information